DK0453898T3 - Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger - Google Patents

Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger

Info

Publication number
DK0453898T3
DK0453898T3 DK91105829.5T DK91105829T DK0453898T3 DK 0453898 T3 DK0453898 T3 DK 0453898T3 DK 91105829 T DK91105829 T DK 91105829T DK 0453898 T3 DK0453898 T3 DK 0453898T3
Authority
DK
Denmark
Prior art keywords
tnf
ischemia
consequences
drug
treatment
Prior art date
Application number
DK91105829.5T
Other languages
English (en)
Inventor
Peter Prof Dr Eckert
Matthias Dr Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0453898T3 publication Critical patent/DK0453898T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91105829.5T 1990-04-25 1991-04-12 Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger DK0453898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (de) 1990-04-25 1990-11-27 Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen

Publications (1)

Publication Number Publication Date
DK0453898T3 true DK0453898T3 (da) 1995-10-09

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91105829.5T DK0453898T3 (da) 1990-04-25 1991-04-12 Anvendelse af TNF-specifikke antistoffer som lægemiddel ved behandlingen af iskæmier og deres følger

Country Status (7)

Country Link
EP (1) EP0453898B1 (da)
JP (1) JPH04364133A (da)
AT (1) ATE123226T1 (da)
DE (2) DE4037604A1 (da)
DK (1) DK0453898T3 (da)
ES (1) ES2073059T3 (da)
IL (1) IL97909A (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions

Also Published As

Publication number Publication date
ATE123226T1 (de) 1995-06-15
EP0453898A3 (en) 1991-12-18
JPH04364133A (ja) 1992-12-16
DE4037604A1 (de) 1991-10-31
EP0453898A2 (de) 1991-10-30
IL97909A (en) 1997-09-30
IL97909A0 (en) 1992-06-21
DE59105609D1 (de) 1995-07-06
EP0453898B1 (de) 1995-05-31
ES2073059T3 (es) 1995-08-01

Similar Documents

Publication Publication Date Title
DE59105609D1 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen.
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
FI906212A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDSin hoidossa
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
FI981591L (fi) AIDS:n hoidossa käyttökelpoisia HIV-proteaasi-inhibiittoreita
ZA913996B (en) Inhibition of viral invection
FI955315A7 (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n ho itoon
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
ES2123156T3 (es) Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
FI935779L (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
TR200401363T4 (tr) DNA viral enfeksiyonlarının tedavisi
NZ306443A (en) Vaccine for treating chlamydia comprising momp protein from chlamydia in conjunction with 3d-mpl and qs21
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
EP0647138A4 (en) POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES.
DK0633928T3 (da) Mikroorganismer, deres fremstilling og anvendelse
FR2713657B1 (fr) Nouveaux vecteurs pour le traitement du sida.
RU2002135207A (ru) Средство "арголит" для лечения инфицированных ран
ATE255594T1 (de) Hepatitis b inhibitoren
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
FI952018A7 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskri ptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon